Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses

Oncotarget

Volumn 7, Issue 29, 2016, Pages 45538-45546

  Xia, Pu ^a   Xu, Xiao Yan ^b  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Bioinformatic analyses; CD44; Colon cancer; Gastric cancer; The cancer genome atlas

Indexed keywords

CD37 ANTIGEN; CD4 ANTIGEN; HERMES ANTIGEN; CD44 PROTEIN, HUMAN; HYALURONIC ACID BINDING PROTEIN; MESSENGER RNA; TUMOR MARKER;

ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CANCER SURVIVAL; COLON CANCER; EVIDENCE BASED MEDICINE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC DATABASE; HUMAN; PHYLOGENY; STOMACH CANCER; SURVIVAL RATE; ADENOCARCINOMA; BIOLOGY; CANCER STEM CELL; COLON TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR;

ADENOCARCINOMA; BIOMARKERS, TUMOR; COLONIC NEOPLASMS; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; HUMANS; HYALURONAN RECEPTORS; KAPLAN-MEIER ESTIMATE; NEOPLASTIC STEM CELLS; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84979937091     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9998     Document Type: Article

References (33)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115-32.
2. Avgustinova A, Benitah SA. The epigenetics of tumour initiation: cancer stem cells and their chromatin. Curr Opin Genet Dev. 2016; 36:8-15.
3. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011; 11:254-67.
4. Screaton GR, Cáceres JF, Mayeda A, Bell MV, Plebanski M, Jackson DG, Bell JI, Krainer AR. Identification and characterization of three members of the human SR family of pre-mRNA splicing factors. EMBO J. 1995; 14:4336-49.
5. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997; 71:241-319.
6. Chanmee T, Ontong P, Kimata K, Itano N. Key Roles of Hyaluronan and Its CD44 Receptor in the Stemness and Survival of Cancer Stem Cells. Front Oncol. 2015; 5:180.
7. Zeilstra J, Joosten SP, van Andel H, Tolg C, Berns A, Snoek M, van de Wetering M, Spaargaren M, Clevers H, Pals ST. Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. Oncogene. 2014; 33:665-70.
8. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 1994; 54:4539-46.
9. Robbins EW, Travanty EA, Yang K, Iczkowski KA. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BMC Cancer. 2008; 8:260.
10. Zhao LH, Lin QL, Wei J, Huai YL, Wang KJ, Yan HY. CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Pathol. 2015; 8:692-701.
11. Wu Y, Li Z, Zhang C, Yu K, Teng Z, Zheng G, Wang S, Liu Y, Cui L, Yu X. CD44 family proteins in gastric cancer: a meta-analysis and narrative review. Int J Clin Exp Med. 2015; 8:3595-606.
12. Chou YE, Hsieh MJ, Hsin CH, Chiang WL, Lai YC, Lee YH, Huang SC, Yang SF, Lin CW. CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan. PLoS One. 2014; 9: e93692.
13. Vazquez A, Grochola LF, Bond EE Levine AJ, Taubert H, Müller TH, Würl P, Bond GL. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res. 2010; 70:172-80
14. Liu Y, Qing H, Su X, Wang C, Li Z, Liu S. Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis. Med Sci Monit. 2015; 21:2694-700.
15. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011; 17:6934-43.
16. Suenaga M, Yamada S, Fuchs BC, Fujii T, Kanda M, Tanaka C, Kobayashi D, Fujiwara M, Tanabe KK, Kodera Y. CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. J Surg Oncol. 2015; 112:622-8.
17. Jing F, Kim HJ, Kim CH, Kim YJ, Lee JH, Kim HR. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases. Int J Oncol. 2015; 46:1582-8.
18. Wang W, Dong LP, Zhang N, Zhao CH. Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis Int J Clin Exp Med. 2014; 7:5059-66.
19. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010; 103:382-90.
20. Hong I, Hong SW, Chang YG, Lee WY, Lee B, Kang YK, Kim YS, Paik IW, Lee H. Expression of the cancer stem cell markers CD44 and CD133 in colorectal cancer: An immunohistochemical staining analysis. Ann Coloproctol. 2015; 31:84-91.
21. Pitule P, Cedikova M, Daum O, Vojtisek J, Vycital O, Hosek P, Treska V, Hes O, Kralickova M, Liska V. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients. Biomed Res Int. 2014; 2014:432139.
22. Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, Joo JK. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 2009; 59:241-6.
23. Setälä L, Lipponen P, Tammi R, Tammi M, Eskelinen M, Alhava E, Kosma VM. Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer. Histopathology. 2001; 138:13-20.
24. Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, Yun JP, Chen YB, Cai MY. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. Surg Oncol. 2013; 107:799-806.
25. Xie JW, Huang CM, Zheng CH, Li P, Wang JB, Lin JX, Lu J. Expression tumor stem cell surface marker CD44 in gastric cancer and its significance. Zhonghua Wei Chang Wai Ke Za Zhi. 2013; 16:1107-12. [Article in Chinese]
26. Guy TV, Terry AM, Bolton HA, Hancock DG, Zhu E, Brink R, McGuire HM, Shklovskaya E, Fazekas de St Groth B. Collaboration between tumor-specific CD4+ T cells and B cells in anti-cancer immunity. Oncotarget. 2016. doi: 10.18632/oncotarget.8797. [Epub ahead of print].
27. Borghese F, Clanchy FI. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets. 2011; 15:237-251.
28. Wilkinson RDA, Magorrian SM, Williams R, Young A, Small DM, Scott CJ, Burden RE. CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner. Oncotarget. 2015; 6:29725-39. doi: 10.18632/oncotarget.5065.
29. Wang ZQ, Milne K, Webb JR, Watson PH. CD74 and intratumoral immune response in breast cancer. Oncotarget. 2016 doi: 10.18632/oncotarget.8610. [Epub ahead of print].
30. Cheng SP, Liu CL, Chen MJ, Chien MN, Leung CH, Lin CH, Hsu YC, Lee JJ. CD74 expression and its therapeutic potential in thyroid carcinoma. Endocr Relat Cancer. 2015; 22:179-90.
31. Kindt N, Lechien JR, Nonclercq D, Laurent G, Saussez S. Involvement of CD74 in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol. 2014; 140:937-47.
32. Otterstrom C, Soltermann A, Opitz I, Felley-Bosco E, Weder W, Stahel RA, Triponez F, Robert JH, Serre-Beinier V. CD74: a new prognostic factor for patients with malignant pleural mesothelioma. Br J Cancer. 2014; 110:2040-6.
33. Shakib PA, Ensani F, Abdirad A, Valizadeh B, Seyedmajidi M, Sum S. CD44 and CD74: The promising candidates for molecular targeted therapy in oral squamous cell carcinoma. Dent Res J (Isfahan). 2015; 12:181-6.